REGENXBIO (RGNX) IPO Opens Up 38%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
REGENXBIO Inc. (Nasdaq: RGNX) to Ring The Nasdaq Stock Market Opening Bell
September 17, 2015 6:00 AM EDTADVISORY, Sept. 17, 2015 (GLOBE NEWSWIRE) --
What:Â
REGENXBIO Inc. (Nasdaq: RGNX), a leading biotechnology company in gene therapy, will visit the Nasdaq MarketSite in Times Square to celebrate its recent initial public offering (IPO).
In honor of the occasion, Ken Mills, President and Chief Executive Officer, will ring the Opening Bell.Â
Where:
Nasdaq MarketSite 4 Times Square 43rd & Broadway Broadcast Studio
When:
Thursday, September 17, 2015 9:15 a.m. to 9:30 a.m. ETÂ Â Â Â Â Â Â Â Â
REGENXBIO Inc. Media Contact:Laura Bagby, 6 Degrees PR(312)... More
REGENXBIO Announces Pricing of Initial Public Offering
September 16, 2015 8:30 PM EDTROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, REGENXBIO granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on September 17, 2015 under the ticker symbol "RGNX."
Morgan Stanley and BofA Merrill Lynch are acting as active joint... More
